Pharmaceutical companies launched new U.S. drugs at prices 35% higher than in 2022, reflecting in part the industry’s embrace of expensive therapies for rare diseases like muscular dystrophy, an analysis found. The median annual list price for a new drug was $300,000 in 2023, according to the analysis of 47 medicines. (Reuters)

Galapagos stopped developing its CAR-T drug candidate in autoimmune diseases, including plans for a trial in systemic lupus erythematosus. This marks the first notable exit from a space that’s been attracting new players. (Endpoints News)

Widespread use of GLP-1 drugs could boost the nation’s gross domestic product by 1% in the coming years, according to an analysis by Goldman Sachs. Some analysts have predicted the market for weight-loss drugs could reach $100 billion per year by the end of the decade, with Novo Nordisk and Eli Lilly leading the race. (The Guardian)

Rick Bright, the former director of BARDA, talked about how AI can democratize the drug development and distribution process. MM+M caught up with Bright, a member of the Cure Xchange Challenge Advisory Board, as well as Cure CEO Seema Kumar, a former executive at Johnson & Johnson, to discuss how AI can revolutionize pandemic responsiveness. (MM+M)

A norovirus outbreak has spread across the Northeast, according to data from the Centers for Disease Control and Prevention. The three-week average positive tests for norovirus in the region reached 13.9 percent in recent weeks and held above a 10 percent positive rate since the middle of December 2023. (The Hill)

Click here to see Friday’s Five things for pharma marketers to know.